IMPACT ON ILLNESS-FREE SURVIVAL (IFS) AND GLOBAL SURVIVAL (GS) OF THE STARTING TIME OF ADJUVANT BREAST CANCER

Author(s)

Villalobos Valencia R1, Soto Molina H2, Díaz Martínez JP3, Victoria Ayala R4, Ayala Anzures M4, Ortiz Rodríguez K4, Valenzuela Martínez M4, Talamantes Gómez E4
1Centro Médico Nacional "La Raza", Mexico City, Mexico, 2Universidad Autónoma Metropolitana, Mexico City, Mexico, 3HS Estudios Farmacoeconómicos, Mexico City, Mexico, 4Centro Médico Nacional, Mexico City, Mexico

OBJECTIVES: To determine if the starting time of chemotherapy influences on illness-free survival and general survival in a cohort of Mexican patients with breast cancer METHODS: A prospective study over 5 years was performed on 88 women with breast cancer from the National Medical Centre “La Raza” of the Mexican Institute of Social Security (IMSS) with the following characteristics: stages I-III and positive criteria for adjuvant chemotherapy. The time range for the chemotherapy administration was 0 to 2, 3 and >4 months. The analysis was performed regarding chemotherapy administration time interval using a Kaplan-Meier estimator. The Cox model was adjusted to see the relationships between the global survival and the oestrogen and progesterone hormone receptor variables and HER2/NEU as well as their basal characteristics.  RESULTS: For both IFS and GS there was a significantly statistical difference on the survival distributions related to starting time of chemotherapy which had a higher probability from a range of 0 to 2 months (median GS 59 months median IFS 49 months; p-value<0.001). Regarding general survival, the hormonal receptors for oestrogen, progesterone and HER2/NEU do not influence on the Cox model (p-value=0.137, 0.823, 0.524 respectively); for the Cox model with basal characteristics, age, pathological state and time interval between surgery and chemotherapy influenced significantly on GS (p-value<0.05)  CONCLUSIONS: The probability of survival for IFS and GS improve when chemotherapy is administered within the first 2 months after surgery. Also, there was a greater risk for GS when time interval between surgery and chemotherapy was prolonged. This delay for the starting time of chemotherapy will impact without a doubt in the health systems´ economy, generating more expenses for attention.

Conference/Value in Health Info

2014-05, ISPOR 2014, Palais des Congres de Montreal

Value in Health, Vol. 17, No. 3 (May 2014)

Code

PCN32

Topic

Clinical Outcomes

Topic Subcategory

Relating Intermediate to Long-term Outcomes

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×